Top Markets
Coin of the day
Petros Pharmaceuticals, Inc. Petros Pharmaceuticals, Inc.

Petros Pharmaceuticals, Inc.

PTPI
Rang in Aktien #40525
Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male... Petros Pharmaceuticals, Inc. is a pharmaceutical company dedicated to male health solutions. Their activities include both the commercialization and ongoing development of Stendra, a prescription PDE-5 inhibitor specifically designed for treating erectile dysfunction (ED). Furthermore, Petros is advancing H100, a proprietary topical formulation currently in development as a potential treatment for acute Peyronie's disease. The company's offerings also extend to a range of erectile dysfunction products, such as vacuum erection devices. Petros Pharmaceuticals, Inc. operates from its base in New York, New York.
Aktienkurs
$0.0034
Marktkapitalisierung
$144.07K
Veränderung (1 Tag)
13.33%
Veränderung (1 Jahr)
-88.67%
Land
US
Handel Petros Pharmaceuticals, Inc. (PTPI)

Kategorie

Dividendenrendite-Verlauf für Petros Pharmaceuticals, Inc. (PTPI)
Dividendenrendite (TTM) von Petros Pharmaceuticals, Inc. (Aktienkürzel: PTPI) zum 2026: 0
Durchschnittliche Dividendenrendite der letzten 5 Jahre: 0.00%
Dividendenrendite-Verlauf für Petros Pharmaceuticals, Inc. (PTPI) von 2026 bis 2026
Dividendenrendite am Ende jedes Jahres (TTM)
Jahr Dividendenrendite ändert
Nicht genügend Daten für die angegebenen Daten.
Dividendenrenditen (TTM) für ähnliche Unternehmen oder Wettbewerber